<DOC>
	<DOCNO>NCT01906671</DOCNO>
	<brief_summary>Acute lymphoblastic leukemia ( ALL ) account 30 % childhood malignancy . The patient undergo four phase treatment , finish late maintenance phase 6-mercaptopurine Methotrexate essential component . Insufficient treatment intensity phase associate increase risk relapse . Excessive variation bioavailability 6-mercaptopurine observed cause risk undertreatment/relapse well overtreatment severe side effect . In attempt achieve individualize 6-mercaptopurine dose different approach pursue . Nonetheless variation bioavailability remain problem . Earlier , oral tablet 50 mg ( Purinethol ) administration form 6-mercaptopurine primarily design adult patient . Challenges accurate dose get child swallow tablet widespread problem , force caregiver divide crush tablet well administer different dosage 2-3 day . Due problem , oral liquid formulation 6-mercaptopurine ( Xaluprine ) develop . However oral liquid test healthy adult volunteer , target group , childhood patient . This project assess bioavailability plasma kinetics oral liquid tablet formulation 6-mercaptopurine child acute lymphoblastic leukemia . The investigator hypothesize observe comparable plasma kinetics , child acute lymphoblastic leukemia treat 6-mercaptopurine form tablet oral liquid formulation , previously observe healthy adult .</brief_summary>
	<brief_title>Study Two Different Formulations 6-mercaptopurine . Tablet Versus Oral Liquid</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Childhood acute lymphoblastic leukemia patient , age 018 year diagnosis , treat department pediatrics adolescent medicine , Rigshospitalet . Informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>6-mercaptopurine</keyword>
	<keyword>Drug formulation</keyword>
</DOC>